Day- and momentum-traders of AVXL should not pay any attention to this posting. It has little validity for the data sets and perspectives of those who are invested in Anavex for near- or mid-term price increases; holders of the stock whose primary purpose is to make a quick or mid-term buck.
I marvel at the plethora of postings where the most minute (even inconsequential) deliberations on anticipated 2-73 clinical results are cogitated on. Those who engage in all of this are certainly welcome to post their astute findings and projections. I, for one, will pay little attention.
I have a small position in AVXL, anticipating that in three to five years it will be very rewarding. Whether the share price appreciates in the coming weeks or months is of no concern to me, because of my belief, based upon my moderate understanding of mitochondrial and endoplasmic reticulum physiology that 2-73 is a remarkable sigma-1 chaperone and is able to restore normal neuron function. This belief derives from the remarkable French work done with 2-73 in genetically-modified rodents who have neuron complications chemically equivalent to Alzheimer’s disease in humans. Simply, in summary, 2-73 fixes neuron anomalies, without untoward or adverse outcomes — at remarkably low concentrations. (I’m a retired biology teacher, who taught these rather arcane subjects).
Yes, before the FDA approves 2-73 for medical use, any number of more complicated and well-controlled human trials will have to be conducted, with demonstrated efficacy and safety. Presently I’m not going to lose any sleep in anxious anticipation of tardy or negative clinical results. The principals of Anavex are very capable researchers and know more about this than anyone who posts here. So much of what’s being posted is pure speculation. The real data exist in Anavex clinical databases, which have been artfully analyzed to guide future clinical trials. Those who work with the clinical 2-73 databases, even just those from rodent subjects, by now know full well the efficacy and safety of 2-73.
All of that, especially human clinical data, will be revealed in good time. Until then, perhaps some time next year, day-trader types will continue to squish incomplete data sets or corporate announcements to guide their trading. My best wishes to all of you who do this. Hope you are rewarded.
Personally, I’ll quietly monitor the postings, and will especially scrutinize any new clinical data that are released. I have every reason to believe they will affirm my efficacy and safety contentions. I’m here for the long-haul. Day to day share price fluctuations are, for me, of no concern or indication.
My best wishes to all — especially to those with the diseases 2-73 should so effectively treat.
